
Opinion|Videos|February 20, 2025
Case presentation: Patient with metastatic CRPC after ARPI and docetaxel for localized PC
Author(s)Abhishek Tripathi, MD
An expert discusses the case of a patient with metastatic castration-resistant prostate cancer (CRPC) who progressed after treatment with androgen receptor pathway inhibitors (ARPI) and docetaxel for localized prostate cancer.
Advertisement
Episodes in this series

Now Playing
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Evaluating the Molecular Landscape in Endometrial Cancer to Optimize Treatment
2
Blinatumomab Plus Chemo Show Improved Survival in Infants with KMT2A-r ALL
3
Bria-IMT Shows Extended Survival in Advanced Metastatic Breast Cancer
4
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
5


















